Abstract: The present invention relates to oral dosage forms of diclofenac, and processes for their manufacture, that provide a rapidly absorbed dose of diclofenac without requiring milling of diclofenac to submicron sizes.

Abstract: An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.

Abstract: An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.

Abstract: An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.

Abstract: This technology is a method and apparatus for the semi-continuous measurement of the concentration of constituents of airborne particles which couples a laminar flow, water condensation particle collector to a microfluidic device for assay of particle chemical composition by electrophoresis. The technology has been used for the assay of sulfates, nitrates, chlorides, and organic acids contained in fine and submicrometer atmospheric particles. For these compounds the apparatus and method described is capable of one-minute time resolution at concentrations at the level of micrograms of analyte species per cubic meter of air. Extension to other analytes is possible.

Abstract: Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid, propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid.

Abstract: Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid, propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid.

Abstract: This technology is a method and apparatus for the semi-continuous measurement of the concentration of constituents of airborne particles which couples a laminar flow, water condensation particle collector to a microfluidic device for assay of particle chemical composition by electrophoresis. The technology has been used for the assay of sulfates, nitrates, chlorides, and organic acids contained in fine and submicrometer atmospheric particles. For these compounds the apparatus and method described is capable of one-minute time resolution at concentrations at the level of micrograms of analyte species per cubic meter of air. Extension to other analytes is possible.

Abstract: Described are solid pharmaceutical compositions for oral administration comprising choline fenofibrate and an amount of an acid sufficient to substantially reduce a rate of dissolution of choline fenofibrate in an aqueous environment at pH 4.5 to less than about 50% in 2 hours. Processes for making the solid pharmaceutical composition for oral administration comprising: (a) mixing choline fenofibrate with an amount of an acid sufficient to substantially reduce a rate of dissolution of choline fenofibrate in an aqueous environment at pH 4.5 to less than about 50% in 2 hours; and (b) preparing a dosage form suitable for oral administration are also provided.

Abstract: The present application relates to an extended-release tablet for oral administration of Clarithromycin. The tablet comprises a water soluble diluent and an acidic compound wherein the acidic compound is used to increase the dissolution rate of Clarithromycin. The tablet is free from polymers or may comprise polymer that is insufficient to function as a release controlling agent.

Abstract: This invention provides a relatively fast and safe method of producing a permanent or nearly permanent skin image, design, or tattoo similar in appearance to that of a solar tattoo. A protective design template is placed on the skin and a cryogenic agent applied to freeze exposed portions of the skin, producing hypopigmentation. An image is defined by the contrast between the treated (hypopigmented) skin and the adjacent untreated skin.

Abstract: Pharmaceutical compositions, which enable high absorption when administered orally, and which comprise a cyclosporin or cyclosporin derivative dissolved in a solvent-surfactant system further comprising a hydrophilic surfactant and a lipophilic surfactant, with minimal quantities of solvents.

Abstract: A capsule comprising venlafaxine hydrochloride wherein part of the drug content is in the form of delayed-release coated spheroids and a second part of the drug content is in a prompt-release form.

Abstract: A novel form of amorphous carvedilol phosphate which is particularly suitable for pharmaceutical applications, and processes for preparing said novel form.

Abstract: Pharmaceutical tablets comprising entacapone and crospovidone.

Abstract: Construction and characterization of microfabricated recessed disk microelectrodes (RDMs) of 14 and 55 ?m diameter are reported. The work reported here makes several new contributions to the current literature on microfabricated RDMs. Hybrid blamers were constructed by fusion of vesicles of dimyristoylphosphatidyl choline (DMPC), which forms the top layer, with ethanol-rinsed SAMs of hexadecanethiol on gold, which form the bottom layer. Gramicidin A was included in the modifying solutions to incorporate it into hybrid blamers.

Abstract: Microcavities and micropores that are microscopic (<1 mm) in width and depth and contain any number of individually-addressable electrodes, separated by insulators, along the walls of each cavity. The conducting materials, and the insulator materials can be deposited alternately onto a starting substrate, which is typically an oxidized silicon wafer or polyimide film, but may be any substrate that shows good adhesion to the materials layered on it. The cavities are etched through these layers, perpendicular to the plane of the substrate, exposing the layers at their edges. Pores may be carved entirely through the device.

Abstract: Stable tablets comprising fosinopril sodium are prepared by employing either stearic acid or zinc stearate as the lubricant.

Abstract: Pharmaceutical tablets comprising clopidogrel bisulfate and a lubricant selected from zinc stearate, stearic acid, and sodium stearyl fumarate.

Abstract: A process of producing the magnesium salt of an enantiomer of omeprazole, said process comprising the steps of: i) reacting magnesium with a lower alcohol to produce magnesium alkoxide in solution in the lower alcohol as solvent, ii) adding the neutral form of the enantiomer of omeprazole to the solution, and iii) flash-evaporating the solvent.